市场调查报告书
商品编码
1491661
心臟辅助设备市场:按类型、模式和最终用户划分 - 全球预测 2024-2030Cardiac Assist Devices Market by Type (Extracorporeal Membrane Oxygenation, Intra-Aortic Balloon Pump (IABP), Total Artificial Hearts (TAH)), Modality (Implantable, Transcutaneous), End User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年心臟辅助设备市场规模为14.6亿美元,预计2024年将达15.5亿美元,2030年将达到22.8亿美元,复合年增长率为6.51%。
心臟辅助设备 (CAD) 是先进的医疗设备,旨在支援和增强心臟衰竭和其他心臟相关疾病患者的心臟泵血功能。 CAD 在末期心臟衰竭患者的管理、与心臟移植、目的地治疗以及术中和术后心臟支持的联繫中发挥着重要作用。由于久坐的生活方式、人口老化以及高血压和糖尿病盛行率的增加,全世界心血管疾病的盛行率不断增加,这增加了对心臟辅助设备的需求。此外,全球对先进心臟支持方案的认识不断提高,以及新兴国家不断上涨的医疗成本也促进了市场成长。此外,与设备植入相关的风险和併发症,例如感染疾病、出血和设备故障,对心臟辅助设备市场的成长构成了重大挑战。此外,提高心臟辅助设备有效性和安全性的技术进步,导致医疗保健提供者和患者更广泛接受,预计将为市场创造成长机会。
主要市场统计 | |
---|---|
基准年[2023] | 14.6亿美元 |
预测年份 [2024] | 15.5亿美元 |
预测年份 [2030] | 22.8亿美元 |
复合年增长率(%) | 6.51% |
区域洞察
由于心血管疾病的高发生率、强大的医疗基础设施以及大量的研发投资,美洲是一个市场格局高度发展的地区。该地区受益于专注于创新并推出技术先进产品的主要市场参与者的存在。美国医疗设备法规和政策也促进了新技术的快速采用。此外,人口老化的加剧和有利的报销方案进一步刺激了市场成长。亚太地区心臟辅助设备市场正在成长,这主要是由于心臟疾病率上升、医疗基础设施改善以及医疗费用上涨。中国、印度等国家人口众多,中等收入阶层不断壮大,为市场拓展提供了巨大机会。该地区也受益于政府旨在改善医疗保健机会的措施。由于先进的医疗保健系统、高昂的医疗成本和心血管疾病的盛行率增加,EMEA(欧洲、中东和非洲)地区的心臟辅助设备前景广阔。德国、英国和法国等国家在有利的医疗政策、高水准的意识层级和完善的医疗基础设施的推动下处于领先地位。由于医疗保健投资的增加和对医疗保健现代化的兴趣日益浓厚,中东地区正在快速增长。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在心臟辅助设备市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对心臟辅助设备市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在心臟辅助设备市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[187 Pages Report] The Cardiac Assist Devices Market size was estimated at USD 1.46 billion in 2023 and expected to reach USD 1.55 billion in 2024, at a CAGR 6.51% to reach USD 2.28 billion by 2030.
Cardiac assist devices (CADs) are sophisticated medical devices designed to support and augment the pumping function of the heart in patients with heart failure or other heart-related conditions. They play a critical role in managing end-stage heart failure patients, providing a bridge to heart transplantation, serving as a destination therapy, or supporting the heart during or after surgeries. The increase in the prevalence of cardiovascular diseases worldwide, attributable to sedentary lifestyles, aging populations, and the rise in hypertension and diabetes, has surged the need for cardiac assist devices. Additionally, the expanding global awareness about the available advanced cardiac support options and the growing healthcare expenditures in emerging economies are also contributing to the market growth. Moreover, the risks and complications associated with device implantation, such as infections, bleeding, and device malfunction, pose significant challenges to the growth of the cardiac assist devices market. Furthermore, technological advancements that improve the efficacy and safety of cardiac assist devices that broaden their acceptance among healthcare providers and patients are expected to create opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.46 billion |
Estimated Year [2024] | USD 1.55 billion |
Forecast Year [2030] | USD 2.28 billion |
CAGR (%) | 6.51% |
Regional Insights
The Americas represents a highly developing landscape for the global market for cardiac assist devices due to the high prevalence of cardiovascular diseases, robust healthcare infrastructure, and significant investments in research and development. The region benefits from the presence of key market players that focus on innovation and launching technologically advanced products. Medical device regulation policies in the US are also conducive to the rapid adoption of new technologies. Moreover, the increasing aging population and favorable reimbursement scenarios further stimulate market growth. The APAC region is witnessing growth in the cardiac assist devices market, attributed mainly to the rising incidence of cardiac diseases, improving healthcare infrastructure, and increasing healthcare expenditure. Countries including China and India, with their vast population bases and growing middle-class, present significant opportunities for market expansion. The region also benefits from government initiatives aimed at improving healthcare access. The EMEA region showcases a strong landscape for cardiac assist devices due to its advanced healthcare system, high healthcare expenditure, and increasing prevalence of cardiovascular diseases. Countries such as Germany, the UK, and France are at the forefront, driven by favorable healthcare policies, high awareness levels, and well-established healthcare infrastructure. The Middle East is rapidly growing due to increasing healthcare investments and a growing focus on healthcare modernization.
Market Insights
The market dynamics represent an ever-changing landscape of the Cardiac Assist Devices Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cardiac Assist Devices Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cardiac Assist Devices Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Supira Medical's Next Generation Percutaneous Ventricular Assist Device (pVAD) System to be Highlighted in a Live Case and Multiple Sessions at the Upcoming TCT 2023 Conference
Supira Medical, Inc. launched a percutaneous ventricular assist device (pVAD), including an anticipated live case demonstration. This inclusion underscores the system's pioneering approach, characterized by its minimal invasiveness and superior continuous flow capabilities, which are poised to revolutionize hemodynamic support for both practitioners and patients alike. [Published On: 2023-10-20]
Abbott Receives FDA Approval for World's First Dual Chamber Leadless Pacemaker
Abbott has received approval from the U.S. Food and Drug Administration (FDA) for its groundbreaking AVEIR DR leadless pacemaker system, marking a significant milestone in cardiac care technology. This innovative system, which is the first of its kind to offer dual chamber leadless pacing, is designed to address the needs of patients experiencing abnormal or slow heart rhythms by providing pacing to both the right atrium and right ventricle. This approval is poised to benefit millions of Americans, as over 80% of pacemaker users require dual-chamber pacing. The AVEIR DR system represents a leap forward in medical technology, providing an expanded range of leadless pacing options and enhancing the treatment capabilities for individuals with heart rhythm disorders. [Published On: 2023-07-05]
UltraLinQ to Launch New Cardiac Monitoring Product at Arab Health
Ultralinq announced the launch of ITS latest product in cardiac monitoring at Arab Health. This innovative solution offers advanced and comprehensive Holter ECG monitoring for improved patient care. The state-of-the-art Holter ECG monitor can record and store up to 14 days of high-quality ECG data. Its user-friendly design simplifies the patient experience and reduces the time spent during clinic appointments. [Published On: 2023-01-31]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cardiac Assist Devices Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Cardiac Assist Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AlivCor Inc., Bardy Diagnostics, Inc., Berlin Heart GmbH, BiVACOR Inc., Boston Scientific Corporation, Cardiac Insight, Inc., Cardiobridge GmbH, CorInnova, Inc., CorWave SA, GE HealthCare Technologies Inc., Getinge AB, Hill-Rom Holdings, Inc., Jarvik Heart Inc., Koninklijke Philips N.V., LivaNova PLC, Medtronic PLC, OSI Systems, Inc., Supira Medical, Teleflex Incorporated, Terumo Corporation, and Xenios AG.
Market Segmentation & Coverage